GBIO Stock Overview
Develops non-viral genetic medicines for the treatment of rare and prevalent diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Generation Bio Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$4.65 |
| 52 Week Low | US$0.75 |
| Beta | 2.66 |
| 1 Month Change | -13.14% |
| 3 Month Change | -54.75% |
| 1 Year Change | -37.70% |
| 3 Year Change | -84.82% |
| 5 Year Change | n/a |
| Change since IPO | -95.18% |
Recent News & Updates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Shareholder Returns
| GBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.6% | -3.8% | -2.7% |
| 1Y | -37.7% | -2.6% | 23.4% |
Return vs Industry: GBIO underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: GBIO underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| GBIO volatility | |
|---|---|
| GBIO Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GBIO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 174 | Geoff McDonough | generationbio.com |
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system.
Generation Bio Co. Fundamentals Summary
| GBIO fundamental statistics | |
|---|---|
| Market cap | US$79.48m |
| Earnings (TTM) | -US$145.47m |
| Revenue (TTM) | US$18.58m |
4.3x
P/S Ratio-0.5x
P/E RatioIs GBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBIO income statement (TTM) | |
|---|---|
| Revenue | US$18.58m |
| Cost of Revenue | US$60.02m |
| Gross Profit | -US$41.44m |
| Other Expenses | US$104.04m |
| Earnings | -US$145.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.18 |
| Gross Margin | -222.99% |
| Net Profit Margin | -782.87% |
| Debt/Equity Ratio | 0% |
How did GBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:24 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Generation Bio Co. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Eun Kyung Yang | Jefferies LLC |
| Farzin Haque | Jefferies LLC |